首页> 外文期刊>Expert opinion on therapeutic targets >Macrophage peroxisome proliferator activated receptor gamma as a therapeutic target to combat Type 2 diabetes.
【24h】

Macrophage peroxisome proliferator activated receptor gamma as a therapeutic target to combat Type 2 diabetes.

机译:巨噬细胞过氧化物酶体增殖物激活受体γ作为对抗2型糖尿病的治疗靶标。

获取原文
获取原文并翻译 | 示例
           

摘要

The peroxisome proliferator activated receptor gamma is a member of the nuclear receptor superfamily of ligand-dependent transcription factors and is the molecular target of antidiabetic thiazolidinediones that exert insulin sensitizing effects in adipose tissue, skeletal muscle and the liver. In addition to the well described effects of peroxisome proliferator activated receptor gamma in insulin target tissues, it is now apparent that its expression in macrophages is critical in the regulation of macrophage phenotype, whole body glucose metabolism and in mediating, in part, the antidiabetic actions of thiazolidinediones. As macrophages are major contributors to tissue inflammation and are resident in tissues responsible for maintaining glucose homeostasis, the therapeutic potential of these cells in the treatment of Type 2 diabetes is of significant clinical interest.
机译:过氧化物酶体增殖物激活受体γ是配体依赖性转录因子的核受体超家族的成员,并且是抗糖尿病噻唑烷二酮的分子靶标,其在脂肪组织,骨骼肌和肝脏中发挥胰岛素致敏作用。除了过氧化物酶体增殖物激活的受体γ在胰岛素靶组织中的良好作用外,现在很明显,它在巨噬细胞中的表达对于调节巨噬细胞表型,全身葡萄糖代谢以及部分介导抗糖尿病作用至关重要噻唑烷二酮。由于巨噬细胞是导致组织炎症的主要因素,并且驻留在负责维持葡萄糖稳态的组织中,因此这些细胞在治疗2型糖尿病中的治疗潜力具有重要的临床意义。

著录项

相似文献

  • 外文文献
  • 中文文献
  • 专利
获取原文

客服邮箱:kefu@zhangqiaokeyan.com

京公网安备:11010802029741号 ICP备案号:京ICP备15016152号-6 六维联合信息科技 (北京) 有限公司©版权所有
  • 客服微信

  • 服务号